Details of Drug

Drug General Information (ID: D0490)
Drug Name	Digitoxin
Drug Type	Small molecule
Drug Synonymous	Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)] Click to Show/Hide
Disease Class	BD10-BD1Z: Heart failure; BC9Z: Cardiac arrhythmia
Therapeutic Class	Antiarrhythmic Agents
Structure
Structure	3D Structure		2D Structure
Formula	C41H64O13
InChI	1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1
InChIKey	WDJUZGPOPHTGOT-XUDUSOBPSA-N
Canonical SMILES	CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CCC7(C6(CCC7C8=CC(=O)OC8)O)C)C)C)C)O)O
External Link
	Pubchem ID	441207
	CAS Number	71-63-6
	CHEBI ID	28544
	TTD ID	D0M3QP
	INTEDE ID	DR0497
	VARIDT ID	DR00239

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM001 Affected gastrointestinal absorption AM002 Affected cellular transport AM003 Affected organization distribution AM004 Affected intra/extra-hepatic metabolism AM005 Affected excretion pathways AM006 Pharmacodynamic additive effects BM002 Altered intestinal flora BM003 Complex formation BM004 Adsorption BM010 Transporter inhibition BM013 Competitive binding of plasma proteins BM014 Interference of cell/tissue uptake BM017 CYP450 enzyme inhibition BM022 CYP450 enzyme induction BM024 Competitive inhibition of metabolic enzyme BM031 Increased renal excretion (Unspecific) BM032 Decreased renal excretion (Unspecific) BM041 Additive hypertensive effects BM042 Additive hypotensive effects BM049 Increased risk of atrioventricular block BM051 Increased risk of bradycardia BM065 Increased risk of hypokalemia BM066 Increased risk of hypomagnesemia BM081 Increased risk of ventricular arrhythmias BM083 Potentiated the pharmacological effects (Unspecific) BM109 Increased risk of other adverse reactions (Unspecific)
Relation Graph

Full list of drugs interacting with Digitoxin
Affected gastrointestinal absorption
	Altered intestinal flora					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0441		Demeclocycline	C21H21ClN2O8	54680690	Moderate		Inter Info	[83], [84], [90], [21]
D0530		Doxycycline	C22H24N2O8	54671203	Moderate		Inter Info	[83], [84], [90], [21]
D1070		Minocycline	C23H27N3O7	54675783	Moderate		Inter Info	[83], [84], [90], [21]
D1564		Tetracycline	C22H24N2O8	54675776	Moderate		Inter Info	[83], [84], [90], [21]
	Complex formation					Drug Num: 11
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0382		Colestipol	C11H28ClN5O	62816	Moderate		Inter Info	[107], [108], [109], [110], [21]
D0877		Kaolin	Al2H4O9Si2	56841936	Moderate		Inter Info	[148], [149], [21]
D0893		Lanthanum carbonate	C3La2O9	168924	Moderate		Inter Info	[153], [28], [29], [154], [155], [156]
D1511		Sucralfate	C12H54Al9O55S8	121494085	Moderate		Inter Info	[192], [193], [194]
D0049		Aluminum hydroxide	AlH3O3	10176082	Minor		Inter Info	[149], [198], [199], [200], [14], [201], [202], [21], [203]
D0968		Magnesium carbonate	CMgO3	11029	Minor		Inter Info	[14], [201], [202]
D0973		Magnesium hydroxide	H2MgO2	14791	Minor		Inter Info	[149], [198], [199], [200], [14], [201], [202], [21], [203]
D1483		Sodium citrate	C6H5Na3O7	6224	Minor		Inter Info	[149], [198], [199], [200], [14], [201], [202], [21], [203]
D1488		Sodium sulfate	Na2O4S	24436	Minor		Inter Info	[14], [201], [202]
D0974		Magnesium oxide	MgO	14792	Minor		Inter Info	[149], [198], [199], [200], [14], [201], [202], [21], [203]
D1480		Sodium bicarbonate	CHNaO3	516892	Minor		Inter Info	[149], [198], [199], [200], [14], [201], [202], [21], [203]
	Adsorption					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0009		Acarbose	C25H43NO18	41774	Moderate		Inter Info	[40], [41]
D0021		Activated charcoal	C	5462310	Moderate		Inter Info	[114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128], [129], [130], [131], [132], [133], [134], [135], [136], [137], [138]
Affected cellular transport
	Transporter inhibition					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0139		Azithromycin	C38H72N2O12	447043	Moderate		Inter Info	[62], [63], [64], [65], [66], [67], [68], [6], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [21], [92], [93], [94], [95], [96], [97], [98], [99], [100]
D0349		Clarithromycin	C38H69NO13	84029	Moderate		Inter Info	[62], [63], [64], [65], [66], [67], [68], [6], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [21], [92], [93], [94], [95], [96], [97], [98], [99], [100]
D0897		Lasmiditan	C19H18F3N3O2	11610526	Moderate		Inter Info	[157]
D0597		Erythromycin	C37H67NO13	12560	Moderate		Inter Info	[62], [63], [64], [65], [66], [67], [68], [6], [69], [70], [71], [72], [73], [74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [21], [92], [93], [94], [95], [96], [97], [98], [99], [100]
Affected organization distribution
	Competitive binding of plasma proteins					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0370		Clozapine	C18H19ClN4	135398737	Moderate		Inter Info	[106]
	Interference of cell/tissue uptake					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1906		Thallous Chloride	ClTl	24642	Moderate		Inter Info	[28], [171], [172]
Affected intra/extra-hepatic metabolism
	CYP450 enzyme inhibition					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0100		Aprepitant	C23H21F7N4O3	135413536	Moderate		Inter Info	[60], [61]
D0693		Fosaprepitant	C23H22F7N4O6P	135413538	Moderate		Inter Info	[60], [61]
D1505		Stiripentol	C14H18O3	5311454	Moderate		Inter Info	[168]
D0894		Lapatinib	C29H26ClFN4O4S	208908	Moderate		Inter Info	[179]
	CYP450 enzyme induction					Drug Num: 10
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0071		Amobarbital	C11H18N2O3	2164	Moderate		Inter Info	[55], [56]
D0224		Butabarbital	C10H16N2O3	2479	Moderate		Inter Info	[55], [56]
D0225		Butalbital	C11H16N2O3	2481	Moderate		Inter Info	[55], [56]
D1040		Methylphenobarbital	C13H14N2O3	8271	Moderate		Inter Info	[55], [56]
D1248		Pentobarbital	C11H18N2O3	4737	Moderate		Inter Info	[55], [56]
D1265		Phenobarbital	C12H12N2O3	4763	Moderate		Inter Info	[55], [56]
D1340		Primidone	C12H14N2O2	4909	Moderate		Inter Info	[55], [56]
D1399		Rifabutin	C46H62N4O11	135398743	Moderate		Inter Info	[184], [185], [186], [187], [188], [189], [190], [191]
D1400		Rifampicin	C43H58N4O12	135398735	Moderate		Inter Info	[184], [185], [191]
D1453		Secobarbital	C12H18N2O3	5193	Moderate		Inter Info	[55], [56]
	Competitive inhibition of metabolic enzyme					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1549		Temsirolimus	C56H87NO16	6918289	Moderate		Inter Info	[169], [170]
D1476		Sirolimus	C51H79NO13	5284616	Moderate		Inter Info	[169], [170]
D1526		Tacrolimus	C44H69NO12	445643	Moderate		Inter Info	[169], [170]
Affected excretion pathways
	Increased renal excretion (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0935		Liotrix	C30H21I7N2Na2O8	71371	Moderate		Inter Info	[161], [162], [163]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[161], [162], [163]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[161], [162], [163]
	Decreased renal excretion (Unspecific)					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1021		Methimazole	C4H6N2S	1349907	Moderate		Inter Info	[180], [181], [182]
D1359		Propylthiouracil	C7H10N2OS	657298	Moderate		Inter Info	[180], [181], [182]
Pharmacodynamic additive effects
	Additive hypertensive effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1066		Milnacipran	C15H22N2O	65833	Moderate		Inter Info	[164]
	Additive hypotensive effects					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0098		Apraclonidine	C9H10Cl2N4	2216	Moderate		Inter Info	[57], [58], [59]
D0205		Brimonidine (ophthalmic)	C11H10BrN5	2435	Moderate		Inter Info	[57], [58], [59]
D0206		Brimonidine (topical)	C11H10BrN5	2435	Moderate		Inter Info	[57], [58], [59]
D0459		Dexmedetomidine	C13H16N2	5311068	Moderate		Inter Info	[28], [33], [111]
	Increased risk of atrioventricular block					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0116		Atazanavir	C38H52N6O7	148192	Major		Inter Info	[23], [24]
D0514		Dolasetron	C19H20N2O3	3033818	Major		Inter Info	[36]
D0363		Clonidine	C9H9Cl2N3	2803	Moderate		Inter Info	[103], [104], [105]
D0885		Lacosamide	C13H18N2O3	219078	Moderate		Inter Info	[150]
D1061		Midodrine	C12H18N2O4	4195	Moderate		Inter Info	[183]
D1522		Sunitinib	C22H27FN4O2	5329102	Moderate		Inter Info	[195], [146]
	Increased risk of bradycardia					Drug Num: 37
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0025		Adenosine	C10H13N5O4	60961	Major		Inter Info	[1], [2], [3]
D0066		Amiodarone	C25H29I2NO3	2157	Major		Inter Info	[4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22]
D0302		Ceritinib	C28H36ClN5O3S	57379345	Major		Inter Info	[28], [29], [30]
D0661		Fingolimod	C19H33NO2	107970	Major		Inter Info	[31], [32]
D1474		Siponimod	C29H35F3N2O3	44599207	Major		Inter Info	[28], [35]
D1444		Saquinavir	C38H50N6O5	441243	Major		Inter Info	[37], [38], [39]
D0010		Acebutolol	C18H28N2O4	1978	Moderate		Inter Info	[42], [43], [44]
D0117		Atenolol	C14H22N2O3	2249	Moderate		Inter Info	[42], [43], [44]
D0173		Betaxolol	C18H29NO3	2369	Moderate		Inter Info	[42], [43], [44]
D0174		Betaxolol (ophthalmic)	C18H29NO3	2369	Moderate		Inter Info	[42], [43], [44]
D0188		Bisoprolol	C18H31NO4	2405	Moderate		Inter Info	[42], [43], [44]
D0266		Carteolol (ophthalmic)	C16H24N2O3	2583	Moderate		Inter Info	[42], [43], [44]
D0267		Carvedilol	C24H26N2O4	2585	Moderate		Inter Info	[42], [43], [44]
D0031		Alectinib	C30H34N4O2	49806720	Moderate		Inter Info	[139], [140]
D0204		Brigatinib	C29H39ClN7O2P	68165256	Moderate		Inter Info	[142]
D0393		Crizotinib	C21H22Cl2FN5O	11626560	Moderate		Inter Info	[29], [145], [146]
D0868		Ivabradine	C27H36N2O5	132999	Moderate		Inter Info	[28], [147]
D0891		Lanreotide	C54H69N11O10S2	71349	Moderate		Inter Info	[151], [152]
D1114		Nebivolol	C22H25F2NO4	71301	Moderate		Inter Info	[42], [43], [44]
D1211		Ozanimod	C23H24N4O3	52938427	Moderate		Inter Info	[165]
D1230		Pasireotide	C58H66N10O9	9941444	Moderate		Inter Info	[153], [28], [29], [166], [167]
D1600		Tofacitinib	C16H20N6O	9926791	Moderate		Inter Info	[28], [146]
D0516		Donepezil	C24H29NO3	3152	Moderate		Inter Info	[175], [176], [177]
D0602		Esmolol	C16H25NO4	59768	Moderate		Inter Info	[42], [43], [44]
D0707		Galantamine	C17H21NO3	9651	Moderate		Inter Info	[175], [176], [177]
D0884		Labetalol	C19H24N2O3	3869	Moderate		Inter Info	[42], [43], [44]
D0915		Levobunolol (ophthalmic)	C17H25NO3	39468	Moderate		Inter Info	[42], [43], [44]
D1045		Metipranolol (ophthalmic)	C17H27NO4	31477	Moderate		Inter Info	[42], [43], [44]
D1049		Metoprolol	C15H25NO3	4171	Moderate		Inter Info	[42], [43], [44]
D1098		Nadolol	C17H27NO4	39147	Moderate		Inter Info	[42], [43], [44]
D1163		Octreotide	C49H66N10O10S2	448601	Moderate		Inter Info	[151], [152]
D1293		Pindolol	C14H20N2O2	4828	Moderate		Inter Info	[42], [43], [44]
D1357		Propranolol	C16H21NO2	4946	Moderate		Inter Info	[42], [43], [44]
D1418		Rivastigmine	C14H22N2O2	77991	Moderate		Inter Info	[175], [176], [177]
D1498		Sotalol	C12H20N2O3S	5253	Moderate		Inter Info	[42], [43], [44]
D1585		Timolol	C13H24N4O3S	33624	Moderate		Inter Info	[42], [43], [44]
D1586		Timolol (ophthalmic)	C13H24N4O3S	33624	Moderate		Inter Info	[42], [43], [44]
	Increased risk of hypokalemia					Drug Num: 19
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0012		Acetazolamide	C4H6N4O3S2	1986	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0058		Amiloride	C6H8ClN7O	16231	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0217		Bumetanide	C17H20N2O5S	2471	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0326		Chlorthalidone	C14H11ClN2O4S	2732	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0479		Diclofenamide	C6H6Cl2N2O4S2	3038	Moderate		Inter Info	[51], [52], [54]
D0731		Glycerin	C3H8O3	753	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0926		Licorice	C42H62O16Zn	163463	Moderate		Inter Info	[158], [159], [160]
D0613		Etacrynic acid	C13H12Cl2O4	3278	Moderate		Inter Info	[51], [52], [54]
D0704		Furosemide	C12H11ClN2O5S	3440	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0771		Hydrochlorothiazide	C7H8ClN3O4S2	3639	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0775		Hydroflumethiazide	C8H8F3N3O4S2	3647	Moderate		Inter Info	[51], [52], [54]
D0798		Indapamide	C16H16ClN3O3S	3702	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D0978		Mannitol	C6H14O6	6251	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D1018		Methazolamide	C5H8N4O3S2	4100	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D1048		Metolazone	C16H16ClN3O3S	4170	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
D1311		Polythiazide	C11H13ClF3N3O4S3	4870	Moderate		Inter Info	[51], [52], [54]
D1605		Tolevamer	C11H16O3S	58817179	Moderate		Inter Info	[29], [197]
D1611		Torasemide	C16H20N4O3S	41781	Moderate		Inter Info	[51], [52], [54]
D1631		Triamterene	C12H11N7	5546	Moderate		Inter Info	[45], [46], [47], [48], [49], [50], [51], [52], [53], [54]
	Increased risk of ventricular arrhythmias					Drug Num: 11
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0067		Amisulpride	C17H27N3O4S	2159	Moderate		Inter Info	[29], [141]
D0510		Dobutamine	C18H23NO3	36811	Moderate		Inter Info	[25], [173], [174]
D0517		Dopamine	C8H11NO2	681	Moderate		Inter Info	[25], [173], [174]
D0581		Epinephrine	C9H13NO3	5816	Moderate		Inter Info	[25], [173], [174]
D0787		Ibutilide	C20H36N2O3S	60753	Moderate		Inter Info	[178]
D0859		Isoprenaline	C11H17NO3	3779	Moderate		Inter Info	[25], [173], [174]
D1153		Norepinephrine	C8H11NO3	439260	Moderate		Inter Info	[25], [173], [174]
D1276		Phenylephrine	C9H13NO2	6041	Moderate		Inter Info	[25], [173], [174]
D1281		Phenylpropanolamine	C9H13NO	26934	Moderate		Inter Info	[25], [173], [174]
D1363		Pseudoephedrine	C10H15NO	7028	Moderate		Inter Info	[25], [173], [174]
D1569		Thalidomide	C13H10N2O4	5426	Moderate		Inter Info	[28], [29], [196]
	Potentiated the pharmacological effects (Unspecific)					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1857		Parathyroid hormone	NA	NA	Major		Inter Info	[29], [33], [34]
D1732		Abaloparatide	C174H300N56O49	145705876	Moderate		Inter Info	[112], [113]
D1901		Teriparatide	C181H291N55O51S2	16133850	Moderate		Inter Info	[112], [113]
	Increased risk of other adverse reactions (Unspecific)					Drug Num: 14
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0237		Calcium chloride	CaCl2H4O2	24844	Major		Inter Info	[25], [26], [27]
D0240		Calcium glucoheptonate	C14H26CaO16	62859	Major		Inter Info	[25], [26], [27]
D0241		Calcium gluconate	C12H22CaO14	9290	Major		Inter Info	[25], [26], [27]
D0233		Calcifediol	C27H44O2	5283731	Moderate		Inter Info	[29], [101], [102]
D0234		Calcitriol	C27H44O3	5280453	Moderate		Inter Info	[29], [101], [102]
D0328		Cholecalciferol	C27H44O	5280795	Moderate		Inter Info	[29], [101], [102]
D0236		Calcium carbonate	CCaO3	10112	Moderate		Inter Info	[143], [144], [26]
D0238		Calcium citrate	C12H10Ca3O14	13136	Moderate		Inter Info	[143], [144], [26]
D0239		Calcium glubionate anhydrous	C18H32CaO19	64776	Moderate		Inter Info	[143], [144], [26]
D0243		Calcium lactate	C6H10CaO6	13144	Moderate		Inter Info	[143], [144], [26]
D0244		Calcium Phosphate	Ca3O8P2	24456	Moderate		Inter Info	[143], [144], [26]
D0527		Doxercalciferol	C28H44O2	5281107	Moderate		Inter Info	[29], [101], [102]
D0591		Ergocalciferol	C28H44O	5280793	Moderate		Inter Info	[29], [101], [102]
D1226		Paricalcitol	C27H44O3	5281104	Moderate		Inter Info	[29], [101], [102]

References
1	Ben-Sorek ES, Wiesel J "Ventricular fibrillation following adenosine administration. A case report." Arch Intern Med 153 (1993): 2701-2.[PMID: 8250667]
2	Mulla N, Karpawich PP "Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed wolff-parkinson-white syndrome treated with digoxin." Pediatr Emerg Care 11 (1995): 238-9.[PMID: 8532572]
3	Product Information. Adenocard (adenosine). Fujisawa, Deerfield, IL.
4	Bajaj BP, Baig MW, Perrins EJ "Amiodarone-induced torsades de pointes: the possible facilitatory role of digoxin." Int J Cardiol 33 (1991): 335-7. [PMID: 1743800]
5	Ben-Chetrit E, Ackerman Z, Eliakim M "Amiodarone-associated hypothyroidism--a possible cause of digoxin intoxication." Am J Med Sci 289 (1985): 114-6. [PMID: 3976714]
6	Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF "P-glycoprotein-mediated intestinal and biliary digoxin transport in humans." Clin Pharmacol Ther 73 (2003): 223-31. [PMID: 12621387]
7	Fenster PE, White NW, Jr Hanson CD "Pharmacokinetic evaluation of the digoxin-amiodarone interaction." J Am Coll Cardiol 5 (1985): 108-12. [PMID: 3964797]
8	Freitag D, Bebee R, Sunderland B "Digoxin-quinidine and digoxin-amiodarone interactions: frequency of occurrence and monitoring in australian repatriation hospitals." J Clin Pharm Ther 20 (1995): 179-83. [PMID: 7593381]
9	Gill J, Heel RC, Fitton A "Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias." Drugs 43 (1992): 69-110. [PMID: 1372862]
10	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]
11	Klein HO, Beker B, DiSegni E, Kaplinsky E "Asystole produced by the combination of amiodarone and digoxin." Am Heart J 113 (1987): 399-400. [PMID: 3544756]
12	Koren G, Hesslein PS, MacLeod SM "Digoxin toxicity associated with amiodarone therapy in children." J Pediatr 104 (1984): 467-70. [PMID: 6707801]
13	Laer S, Scholz H, Buschmann I, Thoenes M, Meinertz T "Digitoxin intoxication during concomitant use of amiodarone." Eur J Clin Pharmacol 54 (1998): 95-6. [PMID: 9591938]
14	Marcus FI "Pharmacokinetic interactions between digoxin and other drugs." J Am Coll Cardiol 5 (1985): a82-90. [PMID: 2985676]
15	McGovern B, Garan H, Kelly E, Ruskin JN "Adverse reactions during treatment with amiodarone hydrochloride." Br Med J (Clin Res Ed) 287 (1983): 175-80. [PMID: 6409240]
16	Mingardi G "Amiodarone and plasma digoxin levels." Lancet 1 (1984): 1238. [PMID: 6144946]
17	Moysey JO, Jaggarao NS, Grundy EN, Chamberlain DA "Amiodarone increases plasma digoxin concentrations." Br Med J (Clin Res Ed) 282 (1981): 272. [PMID: 6779981]
18	Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, Singh BN "Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications." J Am Coll Cardiol 4 (1984): 111-6. [PMID: 6736437]
19	Oetgen WJ, Sobol SM, Tri TB, Heydorn WH, Rakita L "Amiodarone-digoxin interaction: clinical and experimental observations." Chest 86 (1984): 75-9. [PMID: 6734297]
20	Product Information. Cordarone (amiodarone). Wyeth-Ayerst Laboratories, Philadelphia, PA.
21	Rodin SM, Johnson BF "Pharmacokinetic interactions with digoxin." Clin Pharmacokinet 15 (1988): 227-44. [PMID: 3056649]
22	Wilson JS, Podrid PJ "Side effects from amiodarone." Am Heart J 121 (1991): 158-71. [PMID: 1985357]
23	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
24	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
25	Product Information. Lanoxin (digoxin). Glaxo Wellcome, Research Triangle Park, NC.
26	Product Information. PhosLo (calcium acetate) Braintree, Braintree, MA.
27	Product Information. Calcium Gluconate (calcium gluconate). Fresenius Kabi USA, LLC, Lake Zurich, IL.
28	Cerner Multum, Inc. "Australian Product Information.".
29	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
30	Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
31	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
32	FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod).".
33	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
34	Product Information. Natpara (parathyroid hormone). NPS Pharmaceuticals, Bedminster, NJ.
35	Product Information. Mayzent (siponimod). Novartis Pharmaceuticals, East Hanover, NJ.
36	Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO.
37	Product Information. Invirase (saquinavir). Roche Laboratories, Nutley, NJ.
38	Product Information. Invirase (saquinavir mesylate). Astra USA, BAYER HLTHCARE, MA.
39	FDA. U.S. Food and Drug Administration "FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms."
40	Product Information. Precose (acarbose). Bayer, West Haven, CT.
41	Serrano JS, Jimenez CM, Serrano MI, Balboa B "A possible interaction of potential clinical interest between digoxin and acarbose." Clin Pharmacol Ther 60 (1996): 589-92. [PMID: 8941033]
42	Watt DA "Sensitivity to propranolol after digoxin intoxication." Br Med J 2 (1968): 413-4
43	Lowenthal DT, Porter RS, Saris SD, Bies CM, Slegowski MB, Staudacher A "Clinical pharmacology, pharmacodynamics and interactions with esmolol." Am J Cardiol 56 (1985): f14-8
44	Product Information. Zebeta (bisoprolol). Lederle Laboratories, Wayne, NJ.
45	Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
46	Cohen L, Kitzes R "Magnesium Sulfate and digitalis-toxic arrhythmias." JAMA 249 (1983): 2808-10. [PMID: 6842789]
47	Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
48	Macolic V, Vrhovac B "Pharmacokinetics and interactions of digoxin, theophylline and furosemide in diseases with edema." Int J Clin Pharmacol Ther Toxicol 31 (1993): 6-11. [PMID: 8444517]
49	Malcolm AD, Leung FY, Fuchs JC, Duarte JE "Digoxin kinetics during furosemide administration." Clin Pharmacol Ther 21 (1977): 567-74. [PMID: 870271]
50	McAllister RG, Howell SM, Gomer MS, Selby JB "Effect of intravenous furosemide on the renal excretion of digoxin." J Clin Pharmacol 16 (1976): 110-7. [PMID: 943423]
51	Semple P, Tilstone WJ, Lawson DH "Furosemide and urinary digoxin clearance." N Engl J Med 293 (1975): 612-3. [PMID: 902451]
52	Tilstone WJ, Semple PF, Lawson DH, Boyle JA "Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin." Clin Pharmacol Ther 22 (1977): 389-94. [PMID: 902451]
53	Waldorff S, Hansen PB, Kjaergard H, Buch J, Egeblad H, Steiness E "Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride." Clin Pharmacol Ther 30 (1981): 172-6. [PMID: 7249501]
54	Whang R, Oei TO, Watanabe A "Frequency of hypomagnesemia in hospitalized patients receiving digitalis." Arch Intern Med 145 (1985): 655-6. [PMID: 3985729]
55	Cardoso MT, Carvalhas ML. Effects of phenobarbital on digitoxin metabolism in guinea-pig liver slices. Xenobiotica. 1980;10(10):779-784. [PMID: 7456493]
56	Solomon HM, Abrams WB "Interactions between digitoxin and other drugs in man." Am Heart J 83 (1972): 277-80. [PMID: 5058316]
57	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
58	Product Information. Mirvaso (brimonidine topical). Galderma Laboratories Inc, Cranbury, NJ.
59	Walters TR "Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies." Surv Ophthalmol 41 ( Suppl (1996): s19-26
60	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
61	Product Information. Emend for Injection (fosaprepitant). Merck & Company Inc, West Point, PA.
62	Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.?J Pharmacol Sci. 2010;113(4):315-324. [PMID: 20724802]
63	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
64	Balayssac D, Authier N, Cayre A, Coudore F "Does inhibition of P-glycoprotein lead to drug-drug interactions?" Toxicol Lett 156 (2005): 319-29. [PMID: 15763631]
65	Bizjak ED, Mauro VF "Digoxin-macrolide drug interaction." Ann Pharmacother 31 (1997): 1077-82. [PMID: 9296249]
66	Brown BA, Wallace RJ, Griffith DE, Warden R "Clarithromycin-associated digoxin toxicity in the elderly." Clin Infect Dis 24 (1997): 92-3. [PMID: 8994761]
67	Chan AL, Wang MT, Su CY, Tsai FH "Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study." Eur J Clin Pharmacol 65 (2009): 1237-43. [PMID: 19655133]
68	Corallo CE, Rogers IR "Roxithromycin-induced digoxin toxicity." Med J Aust 165 (1996): 433-4. [PMID: 8913245]
69	Eberl S, Renner B, Neubert A, et al. "Role of p-glycoprotein inhibition for drug interactions : evidence from in vitro and pharmacoepidemiological studies." Clin Pharmacokinet 46 (2007): 1039-49. [PMID: 18027988]
70	Ford A, Smith LC, Baltch AL, Smith RP "Clarithromycin-induced digoxin toxicity in a patient with AIDS." Clin Infect Dis 21 (1995): 1051-2. [PMID: 8645810]
71	Friedman HS, Bonventre MV "Erythromycin-induced digoxin toxicity." Chest 82 (1982): 202. [PMID: 7094655]
72	Gomes T, Mamdani MM, Juurlink DN "Macrolide-induced digoxin toxicity: a population-based study." Clin Pharmacol Ther 86 (2009): 383-6. [PMID: 19606089]
73	Gooderham MJ, Bolli P, Fernandez PG "Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin." Ann Pharmacother 33 (1999): 796-9. [PMID: 10466907]
74	Guerriero SE, Ehrenpreis E, Gallagher KL "Two cases of clarithromycin-induced digoxin toxicity." Pharmacotherapy 17 (1997): 1035-7. [PMID: 9324195]
75	Hirata S, Izumi S, Furukubo T, et al. "Interactions between clarithromycin and digoxin in patients with end-stage renal disease." Int J Clin Pharmacol Ther 43 (2005): 30-6. [PMID: 15704612]
76	Hughes J, Crowe A "Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics." J Pharmacol Sci 113 (2010): 315-24. [PMID: 20724802]
77	Hui J, Wang YMC, Chandrasekaran A, Geraets DR, Caldwell JH, Robertson LW, Reuning RH "Disposition of tablet and capsule formulations of digoxin in the elderly." Pharmacotherapy 14 (1994): 607-12. [PMID: 7997395]
78	Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA "Drug-drug interactions among elderly patients hospitalized for drug toxicity." JAMA 289 (2003): 1652-8. [PMID: 12672733]
79	Kiran N, Azam S, Dhakam S "Clarithromycin induced digoxin toxicity: case report and review." J Pak Med Assoc 54 (2004): 440-1. [PMID: 15461217]
80	Kurata Y, Ieiri I, Kimura M, et al. "Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein." Clin Pharmacol Ther 72 (2002): 209-19. [PMID: 12189368]
81	Laberge P, Martineau P "Clarithromycin-induced digoxin intoxication." Ann Pharmacother 31 (1997): 999-1002. [PMID: 9296239]
82	Lee CY, Marcotte F, Giraldeau G, Koren G, Juneau M, Tardif JC "Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature." Can J Cardiol 27 (2011): 870 e15-6. [PMID: 21907534]
83	Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR "Inactivation of digoxin by the gut flora: reversal by antibiotic therapy." N Engl J Med 305 (1981): 789-94. [PMID: 7266632]
84	Lindenbaum J, Tse-Eng D, Butler VP, Rund DG "Urinary excretion of reduced metabolites of digoxin." Am J Med 71 (1981): 67-74. [PMID: 7246583]
85	Maxwell DL, Gilmour-White SK, Hall MR "Digoxin toxicity due to interaction of digoxin with erythromycin." BMJ 298 (1989): 572. [PMID: 2495120]
86	Midoneck SR, Etingin O "Clarithromycin-related toxic effects of digoxin." N Engl J Med 333 (1995): 1505. [PMID: 7477159]
87	Morton MR, Cooper JW "Erythromycin-induced digoxin toxicity." DICP 23 (1989): 668-70. [PMID: 2800579]
88	Nawarskas JJ, McCarthy DM, Spinler SA "Digoxin toxicity secondary to clarithromycin therapy." Ann Pharmacother 31 (1997): 864-6. [PMID: 9220047]
89	Nordt SP, Williams SR, Manoguerra AS, Clark RF "Clarithromycin induced digoxin toxicity." J Accid Emerg Med 15 (1998): 194-5. [PMID: 9639187]
90	Product Information. Lanoxicaps (digoxin). Glaxo Wellcome, Research Triangle Park, NC.
91	Rengelshausen J, Goggelmann C, Burhenne J, et al. "Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction." Br J Clin Pharmacol 56 (2003): 32-38. [PMID: 12848773]
92	Tanaka H, Matsumoto K, Ueno K, et al. "Effect of clarithromycin on steady-state digoxin concentrations." Ann Pharmacother 37 (2003): 178-81. [PMID: 12549942]
93	Ten Eick AP, Reed MD "Hidden dangers of coadministration of antibiotics and digoxin in children: focus on azithromycin." Curr Ther Res 61 (2000): 148-60.
94	Ten Eick AP, Sallee D, Preminger T, Weiss A, Reed MD "Possible drug interaction between digoxin and azithromycin in a young child." Clin Drug Investig 20 (2000): 61-4.
95	Thalhammer F, Hollenstein UM, Locker GJ, et al "Azithromycin-related toxic effects of digitoxin." Br J Clin Pharmacol 45 (1998): 91-2. [PMID: 9489601]
96	Trivedi S, Hyman J, Lichstein E "Clarithromycin and digoxin toxicity." Ann Intern Med 128 (1998): 604. [PMID: 9518419]
97	Tsutsumi K, Kotegawa T, Kuranari M, et al. "The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers." J Clin Pharmacol 42 (2002): 1159-64. [PMID: 12362931]
98	Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K "Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein." Clin Pharmacol Ther 64 (1998): 123-8. [PMID: 9695727]
99	Zapater P, Reus S, Tello A, Torrus D, Perez-Mateo M, Horga JF "A prospective study of the clarithromycin-digoxin interaction in elderly patients." J Antimicrob Chemother 50 (2002): 601-6. [PMID: 12356809]
100	Gurley BJ, Swain A, Williams DK, Barone G, Battu SK "Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics." Mol Nutr Food Res 52 (2008): 772-9. [PMID: 18214850]
101	Product Information. Zemplar (paricalcitol). Abbott Pharmaceutical, Abbott Park, IL.
102	Therapeutic Research Faculty "Natural Medicines Comprehensive Database."
103	Product Information. Cardizem (diltiazem). Hoechst Marion-Roussel Inc, Kansas City, MO.
104	Product Information. Catapres (clonidine). Boehringer-Ingelheim, Ridgefield, CT.
105	Jaffe R, Livshits T, Bursztyn M "Adverse interaction between clonidine and verapamil." Ann Pharmacother 28 (1994): 881-3
106	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
107	Bazzano G, Bazzano GS "Digitalis intoxication. Treatment with a new steroid-binding resin." JAMA 220 (1972): 828-30. [PMID: 5067348]
108	Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia." Drugs 19 (1980): 161-80. [PMID: 6988203]
109	Neuvonen PJ, Kivisto K, Hirvisalo EL "Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide." Br J Clin Pharmacol 25 (1988): 229-33. [PMID: 3358884]
110	Product Information. Colestid (colestipol HCI). Pharmacia and Upjohn, Kalamazoo, MI.
111	Product Information. Precedex (dexmedetomidine) Abbott Pharmaceutical, Abbott Park, IL.
112	Product Information. Forteo (teriparatide). Lilly, Eli and Company, Indianapolis, IN.
113	Benson CT, Voelker JR "Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin." Clin Pharmacol Ther 73 (2003): 87-94. [PMID: 12545147]
114	Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A "Apomorphine test in de novo Parkinson's disease." Funct Neurol 7 (1992): 295-8. [PMID: 1427361]
115	Chernish SM, Wolen RL, Rodda BE "Adsorption of propoxyphene hydrochloride by activated charcoal." Clin Toxicol 5 (1972): 317-29. [PMID: 5073815]
116	Decker WJ, Shpall RA, Corby DG "Inhibition of aspirin absorption by activated charcoal and apomorphine." Clin Pharmacol Ther 10 (1969): 710-3. [PMID: 5808464]
117	Dolgin JG, Nix DE, Sanchez J, Watson WA "Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning: report of two pediatric cases." DICP 25 (1991): 646-9. [PMID: 1877275]
118	Farrar HC, Herold DA, Reed MD "Acute valproic acid intoxication: enhanced drug clearance with oral-activated charcoal." Crit Care Med 21 (1993): 299-301. [PMID: 8428486]
119	Gadgil SD, Damle SR, Advani SH, Vaidya AB "Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate." Cancer Treat Rep 66 (1982): 1169-71. [PMID: 7083219]
120	Glab WN, Corby DG, Decker WJ, Coldiron VR "Decreased absorption of propoxyphene by activated charcoal." J Toxicol Clin Toxicol 19 (1982): 129-38. [PMID: 6125599]
121	Herrington AM, Clifton GD "Toxicology and management of acute drug ingestions in adults." Pharmacotherapy 15 (1995): 182-200. [PMID: 7624266]
122	Howard CE, Roberts RS, Ely DS, Moye RA "Use of multiple-dose activated charcoal in phenytoin toxicity." Ann Pharmacother 28 (1994): 201-3. [PMID: 8173135]
123	Ilkhanipour K, Yealy DM, Krenzelok EP "Activated charcoal surface area and its role in multiple-dose charcoal therapy." Am J Emerg Med 11 (1993): 583-5. [PMID: 8240556]
124	Karkkainen S, Neuvonen PJ "Effect of oral charcoal and urine pH on dextropropoxyphene pharmacokinetics." Int J Clin Pharmacol Ther Toxicol 23 (1985): 219-25. [PMID: 2987139]
125	Kivisto KT, Neuvonen PJ "The effect of cholestyramine and activated charcoal on glipizide absorption." Br J Clin Pharmacol 30 (1990): 733-6. [PMID: 2271372]
126	Knadler MP, Bergstrom RF, Callaghan JT, Obermeyer BD, Rubin A "Absorption studies of the H2-blocker nizatidine." Clin Pharmacol Ther 42 (1987): 514-20. [PMID: 2890459]
127	Naveau S, Bonhomme L, Preaux N, Chaput JC "A pure charcoal suspension for colonoscopic tattoo." Gastrointest Endosc 37 (1991): 624-5. [PMID: 1756921]
128	Neuvonen PJ "Clinical pharmacokinetics of oral activated charcoal in acute intoxications." Clin Pharmacokinet 7 (1982): 465-89. [PMID: 6761032]
129	Orisakwe OE "Activated charcoal: is failure to use it negligence or ignorance?" South Med J 87 (1994): 165-8. [PMID: 8115876]
130	Park GD, Spector R, Goldberg MJ, Johnson GF "Expanded role of charcoal therapy in the poisoned and overdosed patient." Arch Intern Med 146 (1986): 969-73. [PMID: 3516107]
131	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
132	Reed MD "Oral activated charcoal therapy." Am J Emerg Med 6 (1988): 318. [PMID: 3370115]
133	Rowden AM, Spoor JE, Bertino JS, Jr "The effect of activated charcoal on phenytoin pharmacokinetics." Ann Emerg Med 19 (1990): 1144-7. [PMID: 2221521]
134	Saetta JP "Gastric decontaminating procedures: is it time to call a stop?" J R Soc Med 86 (1993): 396-9. [PMID: 8371247]
135	Scheufler E, Bos I "Influence of peroral charcoal on pharmacokinetics and intestinal toxicity of intravenously given methotrexate." Arch Int Pharmacodyn Ther 261 (1983): 180-5. [PMID: 6838279]
136	Wakabayashi Y, Maruyama S, Hachimura K, Ohwada T "Activated charcoal interrupts enteroenteric circulation of phenobarbital." J Toxicol Clin Toxicol 32 (1994): 419-24. [PMID: 8057401]
137	Watson WA "Factors influencing the clinical efficacy of activated charcoal." Drug Intell Clin Pharm 21 (1987): 160-6. [PMID: 3549212]
138	Wing LM, Miners JO, Birkett DJ, et al "Lidocaine disposition: sex differences and effects of cimetidine." Clin Pharmacol Ther 35 (1984): 695-701. [PMID: 6713782]
139	Product Information. Kaletra (lopinavir-ritonavir) Abbott Pharmaceutical, Abbott Park, IL.
140	Product Information. Alecensa (alectinib). Genentech, South San Francisco, CA.
141	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
142	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
143	Davies NT "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc 38 (1979): 121-8. [PMID: 88737]
144	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."
145	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
146	Canadian Pharmacists Association "e-CPS."
147	Product Information. Corlanor (ivabradine). Amgen USA, Thousand Oaks, CA.
148	Albert KS, Ayres JW, DiSanto AR, Weidler DJ, Sakmar E, Hallmark MR, Stoll RG, DeSante KA, Wagner JG "Influence of kaolin--pectin suspension on digoxin bioavailability." J Pharm Sci 67 (1978): 1582-6. [PMID: 712596]
149	Allen MD, Greenblatt DJ, Harmatz JS, Smith TW "Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules." J Clin Pharmacol 21 (1981): 26-30. [PMID: 7012189]
150	Product Information. Vimpat (lacosamide). UCB Pharma Inc, Smyrna, GA.
151	Product Information. Sandostatin (octreotide). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
152	Product Information. Somatuline Depot (lanreotide). Ipsen Inc, Milford, MA.
153	Canadian Pharmacists Association.
154	Product Information. Fosrenol (lanthanum carbonate). Shire US Inc, Florence, KY.
155	Product Information. Nuzyra (omadacycline). Paratek Pharmaceuticals, Inc., Boston, MA.
156	Product Information. Seysara (sarecycline). Allergan Inc, Irvine, CA.
157	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
158	de Klerk GJ, Nieuwenhuis MG, Beutler JJ "Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum." BMJ 314 (1997): 731. [PMID: 9116553]
159	Elinav E, Chajek-Shaul T "Licorice consumption causing severe hypokalemic paralysis." Mayo Clin Proc 78 (2003): 767-8. [PMID: 12934789]
160	Nielsen I, Pedersen RS "Life-threatening hypokalaemia caused by liquorice ingestion." Lancet 1 (1984): 1305. [PMID: 6145019]
161	Frye RL, Braunwald E "Studies on digitalis. III: The influence of triiodothyronine on digitalis requirements." Circulation 23 (1961): 376-82. [PMID: 13702336]
162	Huffman DH, Klaassen CD, Hartman CR "Digoxin in hyperthyroidism." Clin Pharmacol Ther 22 (1977): 533-8. [PMID: 913019]
163	Lawrence JR, Sumner DJ, Kalk WJ, et al "Digoxin kinetics in patients with thyroid dysfunction." Clin Pharmacol Ther 22 (1977): 7-13. [PMID: 872497]
164	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
165	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
166	Product Information. Exelon (rivastigmine) Novartis Pharmaceuticals, East Hanover, NJ.
167	Product Information. Signifor (pasireotide). Novartis Pharmaceuticals, East Hanover, NJ.
168	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
169	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
170	Product Information. Rapamune (sirolimus) Wyeth-Ayerst Laboratories, Philadelphia, PA.
171	Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy "Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl.".
172	Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201). GE Healthcare, Princeton, NJ.
173	Product Information. Claritin-D (loratadine-pseudoephedrine). Schering-Plough, Liberty Corner, NJ.
174	Product Information. Epinephrine Hydrochloride Injection (epinephrine). Abbott Pharmaceutical, Abbott Park, IL.
175	Product Information. Cognex (tacrine). Parke-Davis, Morris Plains, NJ.
176	Product Information. Razadyne (galantamine). Johnson and Johnson Medical Inc, Arlington, TX.
177	Tiseo PJ, Perdomo CA, Friedhoff LT "Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes." Br J Clin Pharmacol 46(Suppl 1) (1998): 40-4
178	Product Information. Corvert (ibutilide). Pharmacia and Upjohn, Kalamazoo, MI.
179	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
180	Product Information. Tapazole (methimazole). King Pharmaceuticals Inc, Bristol, TN.
181	Product Information. Propylthiouracil (propylthiouracil). Lederle Laboratories, Wayne, NJ.
182	Doherty JE, Perkins WH "Digoxin metabolism in hypo- and hyperthyroidism. Studies with tritiated digoxin in thyroid disease." Ann Intern Med 64 (1966): 489-507
183	Product Information. ProAmatine (midodrine). Roberts Pharmaceutical Corporation, Eatontown, NJ.
184	Boman G, Eliasson K, Odar-Cederlof I "Acute cardiac failure during treatment with digoxin--an interaction with rifampicin." Br J Clin Pharmacol 10 (1980): 89-90. [PMID: 7397060]
185	Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
186	Bussey HI, Merritt GJ, Hill EG "The influence of rifampin on quinidine and digoxin." Arch Intern Med 144 (1984): 1021-3. [PMID: 6712395]
187	Novi C, Bissoli F, Simonati V, Volpini T, Baroli A, Vignati G "Rifampin and digoxin: possible drug interaction in a dialysis patient." JAMA 244 (1980): 2521-2. [PMID: 7431585]
188	Poor DM, Self TH, Davis HL "Interaction of rifampin and digitoxin." Arch Intern Med 143 (1983): 599. [PMID: 6830398]
189	Product Information. Rifadin (rifampin). Hoechst Marion-Roussel Inc, Kansas City, MO.
190	Strayhorn VA, Baciewicz AM, Self TH "Update on rifampin drug interactions, III." Arch Intern Med 157 (1997): 2453-8. [PMID: 9385296]
191	Venkatesan K "Pharmacokinetic drug interactions with rifampicin." Clin Pharmacokinet 22 (1992): 47-65. [PMID: 1559307]
192	McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25. [PMID: 1886624]
193	Product Information. Carafate (sucralfate). Hoechst Marion-Roussel Inc, Kansas City, MO.
194	Rey AM, Gums JG "Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration." DICP 25 (1991): 745-6. [PMID: 1949932]
195	Product Information. Sutent (sunitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
196	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
197	Product Information. Kayexalate (sodium polystyrene sulfonate). Sanofi Winthrop Pharmaceuticals, New York, NY.
198	Bonelli J, Hruby K, Magometschnigg D, Hitzenberger G, Kaik G "The bio-availability of beta-acetyldigoxine alone and combined with aluminum hydroxide and magnesium hydroxide (Alucol)." Int J Clin Pharmacol Biopharm 15 (1977): 337-9. [PMID: 892951]
199	Brown DD, Juhl RP "Decreased bioavailability of digoxin due to antacids and kaolin-pectin." N Engl J Med 295 (1976): 1034-7. [PMID: 972657]
200	D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
201	McElnay JC, Harron DW, D'Arcy PF, Eagle MR "Interaction of digoxin with antacid constituents." Br Med J 1 (1978): 1554. [PMID: 656806]
202	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
203	Liu F, Qiu M, Zhai SD. Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis.?Curr Ther Res Clin Exp. 2010;71(1):1-29. [PMID: 24683248]

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence